{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:03:09Z","timestamp":1761742989571},"reference-count":14,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5241,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1998,11]]},"abstract":"<jats:p>This study was designed to investigate the interaction between high\u2010dose oral ganciclovir (6,000 mg\/day) and didanosine at steady state in patients who were seropositive for human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infection. The study was conducted as an open\u2010label, randomized, three\u2010period crossover study. Patients received (in random order) multiple oral doses of didanosine 200 mg every 12 hours alone, ganciclovir 2,000 mg every 8 hours alone, and ganciclovir 2,000 mg every 8 hours in combination with didanosine 200 mg every 12 hours. Blood and urine samples for determinations of drug concentrations were obtained on day 3 of each dose regimen. When ganciclovir was administered either before or 2 hours after didanosine, the mean increases in maximum concentration (C<jats:sub>max<\/jats:sub>), area under the concentration\u2014time curve (AUC<jats:sub>0\u201312<\/jats:sub>), and percent excreted in urine of didanosine were 58.6% and 87.3%, 87.3% and 124%, and 100% and 153%, respectively. There were no statistically significant effects of didanosine on the steady\u2010state pharmacokinetics of ganciclovir in the presence of didanosine, irrespective of sequence of administration. There were no significant changes in renal clearance of didanosine, suggesting that the mechanism for the interaction does not involve competition for active renal tubular secretion. The mechanism responsible for increased didanosine concentrations and percent excreted in urine during concurrent ganciclovir therapy may be a result of increased bioavailability of didanosine. However, the mechanism appears to be saturated at oral ganciclovir doses of 3 g\/day.<\/jats:p>","DOI":"10.1177\/009127009803801111","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T00:52:18Z","timestamp":1182473538000},"page":"1057-1062","source":"Crossref","is-referenced-by-count":16,"title":["Effect of High\u2010Dose Oral Ganciclovir on Didanosine Disposition in Human Immunodeficiency Virus (HIV)\u2010Positive Patients"],"prefix":"10.1002","volume":"38","author":[{"given":"Donald","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Griffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Raschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Tarnowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hulse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"194","article-title":"Cytomegalovirus infection in patients with AIDS","volume":"6","author":"Drew WL","year":"1992","journal-title":"Clin Infect Dis"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509073331002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1431"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.8.1251"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0149-2918(95)80107-3"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-3-368"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.86"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199803010-00007"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00381-9"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)82215-X"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.137"},{"key":"e_1_2_1_13_2","first-page":"204","article-title":"Treatment with 2\u2032,3\u2032\u2010dideoxyinosine given twice daily to patients with cytomegalovirus retinitis receiving maintenance DHPG (ganciclovir) (abstract no. SB474)","volume":"6","author":"Liebman HA","year":"1990","journal-title":"Int Conf AIDS"},{"key":"e_1_2_1_14_2","first-page":"6","article-title":"Two multiple crossover studies of IV ganciclovir and didanosine in HIV infected persons (abstract)","volume":"35","author":"Frascino RJ","year":"1995","journal-title":"Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 17\u201320 September, 1995. Washington, DC: American Society of Microbiology"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90235-8"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F009127009803801111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/009127009803801111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T15:38:00Z","timestamp":1698507480000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/009127009803801111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,11]]}},"alternative-id":["10.1177\/009127009803801111"],"URL":"https:\/\/doi.org\/10.1177\/009127009803801111","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,11]]}}}